Novartis, CH0012005267

Novartis wins FDA approval as Novartis stock stands at EUR 135.15

Published on 10/20/2026 at 09:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rhapsido won a second US indication on October 7, 2026. Novartis stock stood at EUR 135.15 as Q2 sales reached USD 14.95 billion.

Pipeline dates frame the story

Rhapsido achieved complete hive resolution for 29.30 percent of patients versus 14.00 percent for placebo on October 7, 2026.
Second-quarter sales reached USD 14.95 billion, up 3.00 percent in US dollars.
Novartis stock traded at EUR 135.15 at 9:18 a.m. CEST at Lang & Schwarz on October 20, 2026.
Novartis scheduled an investor call for October 23, 2026 and third-quarter results for October 27, 2026.

Extreme Nahaufnahme einer weißen Tablette mit Bruchkerbe und feiner granularer Textur — Novartis AG CH0012005267 – Extreme Makroaufnahme einer weißen Tablette mit Bruchkerbe und feiner Oberflächentextur, Illustration mit AI erstellt.

Novartis stock (ISIN CH0012005267) was trading at EUR 135.15 at Lang & Schwarz on October 20, 2026 at 9:18 a.m. CEST. The company had won US approval for Rhapsido on October 7, expanding the drug's use to symptomatic dermographism, according to Novartis.

Rhapsido adds a second indication

The FDA decision gives Rhapsido an approved use for adults with symptomatic dermographism whose symptoms remain inadequately controlled by H1 antihistamines. The treatment already covered chronic spontaneous urticaria, making the October 7, 2026 decision a label expansion rather than a first US approval.

The Phase III RemIND study supplied the supporting evidence. At Week 12, complete hive resolution reached 29.30 percent with remibrutinib, versus 14.00 percent with placebo, according to the Novartis release. That 15.30 percentage-point gap gives investors a measurable clinical marker for the product's commercial expansion.

Three dated events shape the pipeline

On July 21, 2026, Novartis reported second-quarter sales of USD 14.95 billion, up 3.00 percent in US dollars, while core operating income was USD 5.94 billion and broadly flat year over year, according to TickerScout. On October 2, 2026, the company was reported to have signed an mRNA deal with Abogen valued at USD 7.20 billion. On October 7, 2026, the Rhapsido approval added the second indication.

Upcoming dates carry the next test

Novartis scheduled a Remibrutinib investor call for October 23, 2026, followed by third-quarter results on October 27, 2026. The results will test whether the company's first-half sales base of USD 27.52 billion can support its full-year outlook.

What does sales mix mean?

The second-quarter figures show the tension between newer growth products and older medicines facing competition. Reported net income was USD 3.26 billion in the quarter, while operating income reached USD 4.75 billion, leaving the October results as the next quantified update on margin resilience.

Stock enters the October events

The EUR 135.15 Lang & Schwarz quote places the stock at a visible market level as the company approaches two scheduled investor events. The next earnings release should provide the clearest update on sales growth, operating income and the commercial contribution of Rhapsido.

The further course of trading is shown by the continuously updated real-time quote of Novartis stock.